Company profile for Aptinyx

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Aptinyx Inc. is a clinical-stage biopharmaceutical company discovering and developing transformative therapies for challenging disorders of the brain and nervous system. Aptinyx has a proven platform for discovery of novel compounds that work through a unique mechanism to modulate — rather than block or over-activate — NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. We believe l...
Aptinyx Inc. is a clinical-stage biopharmaceutical company discovering and developing transformative therapies for challenging disorders of the brain and nervous system. Aptinyx has a proven platform for discovery of novel compounds that work through a unique mechanism to modulate — rather than block or over-activate — NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. We believe leveraging the therapeutic advantages of this differentiated mechanism will drive a paradigm shift in the treatment of numerous disorders of the brain and nervous system.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
909 Davis Street, Suite 600 Evanston, IL 60201
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://endpts.com/remember-that-record-biotech-ipo-party-in-2018-there-was-no-happily-ever-after/

ENDPTS
08 May 2023

https://endpts.com/aptinyx-evaluates-future-of-the-company-following-two-failed-trials-60-layoffs/

Katherine Lewin ENDPTS
31 Mar 2023

https://www.businesswire.com/news/home/20230330005712/en

BUSINESSWIRE
30 Mar 2023
Aptinyx dumps dementia drug, stops PTSD trial after phase 2 flop
Aptinyx dumps dementia drug, stops PTSD trial after phase 2 flop

28 Feb 2023

// Nick Paul Taylor FIERCE BIOTECH

https://www.fiercebiotech.com/biotech/aptinyx-reeling-series-setbacks-dumps-dementia-drug-stops-ptsd-trial-after-phase-2-flop

Nick Paul Taylor FIERCE BIOTECH
28 Feb 2023

https://www.businesswire.com/news/home/20230227005764/en

BUSINESSWIRE
27 Feb 2023

https://www.businesswire.com/news/home/20230131005510/en

BUSINESSWIRE
31 Jan 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty